ImmunityBio is dedicated to conquering cancer. We develop therapies that kill disease, not the immune system. Learn about our investigational immunotherapy and cell therapy products.
Location: United States, California, Culver City
Employees: 51-200
Founded date: 2002
Investors 1
| Date | Name | Website |
| - | Avoro Capi... | avorocapit... |
Mentions in press and media 9
| Date | Title | Description |
| 23.11.2020 | Drugmakers behind 3 coronavirus vaccines say they work. Here's everything we know about the race for a vaccine and when you might be able to get a shot. | A pharmacist gives Jennifer Haller, left, the first shot in the first-stage safety study clinical trial of a potential vaccine for COVID-19, the disease caused by the new coronavirus, Monday, March 16, 2020, at the Kaiser Permanente Washing... |
| 08.01.2020 | At 2020 deadline, progress in Patrick Soon-Shiong’s ‘cancer moonshot’ is hard to find | In 2016, the biotech billionaire Dr. Patrick Soon-Shiong set himself a deadline: By 2020, he would transform the fight against cancer. With the help of a coalition of big-name companies, researchers, and physicians, Soon-Shiong vowed, he wo... |
| 26.03.2019 | NantKWest Raises $39 Million From Company Founder Patrick Soon-Shiong | - |
| 06.02.2018 | New Union-Tribune owner ambitious, controversial | Patrick Soon-Shiong, the billionaire medical entrepreneur who this morning has agreed to buy the Los Angeles Times and the Union-Tribune, made his fortune fighting cancer and his name pursuing ambitious projects. “Push yourself!” he said in... |
| 06.04.2017 | Viracta Therapeutics Holds Initial Close of Series B Funding of up to $18.4M | Viracta Therapeutics, Inc., a San Diego, CA-based clinical-stage drug development company, held the initial closing of a Series B financing round of up to $18.4m. The round was led by NantKwest, Inc. (NASDAQ:NK) with participation from new ... |
| 27.03.2017 | Soon-Shiong’s promotion of ‘breakthrough’ cancer therapy raises questions | The emotional video tells of a patient with blood cancer who tries an experimental therapy involving “natural killer” cells. “NEW BREAKTHROUGH HELPS PATIENTS KILL CANCER” the banner headline declares as the patient, wiping away tears, cover... |
| 29.06.2016 | The biotech IPO feast flags as investors lose their appetite for R&D risk | There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. But from 2013 through 2015 generalist investors got over their fears and jumped into one of the hottest stock games on the planet. Fund... |
| 29.11.2015 | NantHealth to delay IPO in face of tough market | NantHealth, the health IT and analytics branch of Dr. Patrick Soon-Shiong‘s NantWorks conglomerate, will put off a planned initial public offering until the healthcare investment climate improves, Soon-Shiong said in an interview with the L... |
| - | NantHealth to delay IPO in face of tough market | NantHealth, the health IT and analytics branch of Dr. Patrick Soon-Shiong‘s NantWorks conglomerate, will put off a planned initial public offering until the healthcare investment climate improves, Soon-Shiong said in an interview with the L... |